We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ionis Pharmaceuticals Inc | NASDAQ:IONS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 39.47 | 39.29 | 62.00 | 0 | 09:00:04 |
From May 2023 to May 2024
By Colin Kellaher
Ionis Pharmaceuticals is teaming up with longtime partner Roche Holdings on a pair of early stage programs for RNA-targeting investigational medicines for the treatment of the brain disorders Alzheimer's disease and Huntington's disease.
Ionis on Wednesday said it will have responsibility to advance the two programs through pre-clinical studies, while Roche will have sole responsibility for clinical development and commercialization worldwide.
Ionis said it will receive a $60 million upfront payment from Roche, adding that it is eligible for development, regulatory and commercial milestone payments, along with royalties.
Carlsbad, Calif.-based Ionis and Swiss drug giant Roche have been working together since 2013 and have candidates in clinical studies targeting Huntington's, IgA nephropathy and geographic atrophy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 27, 2023 07:44 ET (11:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Ionis Pharmaceuticals Chart |
1 Month Ionis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
